Jump to content

Main menu Navigation ●Main page ●Contents ●Current events ●Random article ●About Wikipedia ●Contact us ●Donate Contribute ●Help ●Learn to edit ●Community portal ●Recent changes ●Upload file

●Create account ●Log in ●Create account ● Log in Pages for logged out editors learn more ●Contributions ●Talk

(Top) 1 References

N-Desmethyltamoxifen

Add links ●Article ●Talk ●Read ●Edit ●View history Tools Actions ●Read ●Edit ●View history General ●What links here ●Related changes ●Upload file ●Special pages ●Permanent link ●Page information ●Cite this page ●Get shortened URL ●Download QR code ●Wikidata item Print/export ●Download as PDF ●Printable version Appearance From Wikipedia, the free encyclopedia (Redirected from ICI-55548)

N-Desmethyltamoxifen
Clinical data

Other names	ICI-55,548; Nortamoxifen; NDMTAM
Drug class	Selective estrogen receptor modulator
Identifiers
IUPAC name 2-[4-[(Z)-1,2-Diphenylbut-1-enyl]phenoxy]-N-methylethanamine
CAS Number	31750-48-8
PubChem CID	6378383
ChemSpider	2297759
UNII	OOJ759O35C
KEGG	C16546
ChEBI	CHEBI:80554
CompTox Dashboard (EPA)	DTXSID501315924
ECHA InfoCard	100.170.899
Chemical and physical data
Formula	C₂₅H₂₇NO
Molar mass	357.497 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCNC)/C3=CC=CC=C3
InChI InChI=1S/C25H27NO/c1-3-24(20-10-6-4-7-11-20)25(21-12-8-5-9-13-21)22-14-16-23(17-15-22)27-19-18-26-2/h4-17,26H,3,18-19H2,1-2H3/b25-24- Key:NYDCDZSEEAUOHN-IZHYLOQSSA-N

N-Desmethyltamoxifen (developmental code name ICI-55,548) is a major metaboliteoftamoxifen, a selective estrogen receptor modulator (SERM).^[1]^[2] N-Desmethyltamoxifen is further metabolized into endoxifen (4-hydroxy-N-desmethyltamoxifen), which is thought to be the major active form of tamoxifen in the body.^[1]^[2]^[3] In one study, N-desmethyltamoxifen had an affinity for the estrogen receptor of 2.4% relative to estradiol.^[4] For comparison, tamoxifen, endoxifen, and afimoxifene (4-hydroxytamoxifen) had relative binding affinities of 2.8%, 181%, and 181%, respectively.^[4]

References

[edit]

^ ^a ^b Sanchez-Spitman AB, Swen JJ, Dezentje VO, Moes DJ, Gelderblom H, Guchelaar HJ (June 2019). "Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen". Expert Review of Clinical Pharmacology. 12 (6): 523–536. doi:10.1080/17512433.2019.1610390. PMID 31008668.

^ ^a ^b Klein DJ, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE (November 2013). "PharmGKB summary: tamoxifen pathway, pharmacokinetics". Pharmacogenet Genomics. 23 (11): 643–7. doi:10.1097/FPC.0b013e3283656bc1. PMC 4084801. PMID 23962908.

^ Binkhorst L, Mathijssen RH, Jager A, van Gelder T (March 2015). "Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping". Cancer Treat Rev. 41 (3): 289–99. doi:10.1016/j.ctrv.2015.01.002. PMID 25618289.